Abiopharma

🔍 Chambers Rebecca (Executive)

Company: VERACYTE, INC. (VCYT)

Report Date: 2026-06-02

Detailed Transactions and Holdings:

• Sold 3,693 shares of Common Stock at $47.8 per share (Direct)
  Date: 2026-06-02 | Code: F | equity_swap_involved: 0 | shares_owned_after: 176,841.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,600 shares of Common Stock at $49.2836 per share (Direct)
  Date: 2026-06-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 175,241.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 1,961 shares of Common Stock at $50.0913 per share (Direct)
  Date: 2026-06-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 173,280.00 | transaction_form_type: 4 | Footnotes: F2, F4

Footnotes:

• F1: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale.
• F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.
• F3: Represents weighted average sales price. Sale prices for the transactions range from $48.80 to $49.74. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
• F4: Represents weighted average sales price. Sale prices for the transactions range from $49.88 to $50.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.